ANNOUNCEMENT

Check out the MedCity CONVERGE speaker lineup: Pfizer, Cleveland Clinic, Intel and more.

Morning Read: Cancer, infectious disease top areas for biopharma dealmaking

June 1, 2012 8:59 am by | 0 Comments

Where are the deals in biopharma? A new analysis of 714 licensing deals and joint ventures from Deloitte shows that cancer was the most active therapeutic area last year, with 161 deals. Infectious disease and neurology has the second and third highest number of deals. Although there were fewer deals in autoimmune & inflammatory diseases and endocrine & metabolic conditions, these areas had high median deal sizes.

Most CEOs of publicly traded health plans saw their salaries go up last year along with company income. The top execs of the seven largest publicly traded health plans made $87 million last year, with Cigna CEO David Cordani making the most ($19.1 million) and Humana’s Mike McCallister making the least ($7.3 million), according to an American Medical News analysis of SEC filings.

Merck won’t be following in the footsteps of Abbott and Pfizer in splitting up the business. ’My philosophy is fix what is broke, don’t do the fad of the day,’ CEO Ken Frazier said at the Sanford C. Bernstein conference yesterday in New York.

Stanford’s StartX accelerator is expanding this summer by creating a program to work specifically with biotech and medical startups. Eleven companies led by Stanford students, faculty will participate in the six-month program.

Advertisement

Even the most aggressive states that have pushed to get their health insurance exchanges up and running fear they won’t be ready for enrollment by the 2014 deadline. The problem? Information technology.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.

Know What's Next in Medical Innovation

Get the latest stories, carefully selected by our editorial team, in your inbox each morning.


Related Topics: ,

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments

Stay Up To Date

Next Story
‘Pattern recognition’ allowed VC to see promise in electronically-focusing glasses
Close